• Tue news: Pfizer explores sale of hospital drugs unit. FDA declines full approval of Ocaliva. AZ better than expected Q3 results. Pfizer, Lilly telehealth platforms draw scrutiny. 23andMe cutting lays off 40%. See more on our front page

Valneva, Pfizer delay end date of Lyme disease vaccine phase 3 trial to 2025

cafead

Administrator
Staff member
  • cafead   Mar 26, 2023 at 11:13: PM
via Valneva (VALN) and Pfizer (PFE) have pushed back by a year the end date of a phase 3 trial for their Lyme disease vaccine candidate VLA15.

article source